| Literature DB >> 21807507 |
Mark W Holladay1, Brian T Campbell, Martin W Rowbottom, Qi Chao, Kelly G Sprankle, Andiliy G Lai, Sunny Abraham, Eduardo Setti, Raffaella Faraoni, Lan Tran, Robert C Armstrong, Ruwanthi N Gunawardane, Michael F Gardner, Merryl D Cramer, Dana Gitnick, Mark A Ator, Bruce D Dorsey, Bruce R Ruggeri, Michael Williams, Shripad S Bhagwat, Joyce James.
Abstract
Aryl phenyl ureas with a 4-quinazolinoxy substituent at the meta-position of the phenyl ring are potent inhibitors of mutant and wild type BRAF kinase. Compound 7 (1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea hydrochloride) exhibits good pharmacokinetic properties in rat and mouse and is efficacious in a mouse tumor xenograft model following oral dosing.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21807507 DOI： 10.1016/j.bmcl.2011.07.019
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823